|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Yescarta
gptkb:Immunomedics
Pharmacyclics
|
|
gptkbp:areaServed
|
Global
|
|
gptkbp:awards
|
Best Places to Work
Innovative_Company_Award
|
|
gptkbp:CEO
|
gptkb:Daniel_O'Day
|
|
gptkbp:clinicalTrials
|
HIV treatments
Hepatitis C treatments
Oncology treatments
|
|
gptkbp:communityEngagement
|
HIV prevention programs
Hepatitis C awareness campaigns
|
|
gptkbp:communitySupport
|
Support for local charities
Health education initiatives
Access to medicines programs
|
|
gptkbp:employees
|
500+
|
|
gptkbp:financialPerformance
|
Revenue growth
Profit margins
Market capitalization
|
|
gptkbp:focus
|
Antiviral drugs
|
|
gptkbp:founded
|
2001
|
|
gptkbp:headquarters
|
gptkb:Ireland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gilead Sciences Ireland UC
|
|
gptkbp:industry
|
Biotechnology
|
|
gptkbp:market
|
gptkb:Asia
gptkb:Latin_America
gptkb:North_America
Europe
|
|
gptkbp:parentCompany
|
gptkb:Gilead_Sciences,_Inc.
|
|
gptkbp:partnerships
|
gptkb:Galapagos_NV
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb
gptkb:Merck_&_Co.
|
|
gptkbp:philanthropy
|
gptkb:Gilead_Foundation
|
|
gptkbp:products
|
gptkb:Atripla
gptkb:Truvada
Biktarvy
Descovy
|
|
gptkbp:regulatoryCompliance
|
EMA_approved_drugs
FDA_approved_drugs
|
|
gptkbp:researchAndDevelopment
|
Significant investment
Innovative therapies
|
|
gptkbp:researchFocus
|
HIV
Hepatitis C
Inflammatory diseases
|
|
gptkbp:subsidiary
|
gptkb:Gilead_Sciences,_Inc.
|
|
gptkbp:sustainabilityInitiatives
|
Greenhouse gas reduction
Waste reduction programs
Water conservation efforts
|
|
gptkbp:training
|
Leadership development
Continuous education programs
Diversity and inclusion training
|
|
gptkbp:website
|
www.gilead.com
|